Search Results - "Hanson, C A"

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia by Pardanani, A, Lasho, T L, Laborde, R R, Elliott, M, Hanson, C A, Knudson, R A, Ketterling, R P, Maxson, J E, Tyner, J W, Tefferi, A

“…Truncation mutations of the receptor cytoplasmic domain for colony-stimulating factor 3 (CSF3R) are frequently seen in severe congenital neutropenia, whereas…”
Get full text

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients by Tefferi, A, Guglielmelli, P, Lasho, T L, Rotunno, G, Finke, C, Mannarelli, C, Belachew, A A, Pancrazzi, A, Wassie, E A, Ketterling, R P, Hanson, C A, Pardanani, A, Vannucchi, A M

“…Current prognostication in primary myelofibrosis (PMF) is based on the dynamic international prognostic scoring system (DIPSS)-plus, which employs clinical and…”
Get full text

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera by PARDANANI, A, ASHO, T. L, INKE, C. F, HANSON, C. A, TEFFERI, A

“…After accounting for misdiagnosis and treatment effect, allele-specific (AS)-PCR detects the JAK2V617F mutation in >95% of polycythemia vera (PV) patients…”
Get full text

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact by Tefferi, A, Lasho, T L, Finke, C, Belachew, A A, Wassie, E A, Ketterling, R P, Hanson, C A, Pardanani, A

Get full text

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients by Guglielmelli, P, Lasho, T L, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, Biamonte, F, Pardanani, A, Zoi, K, Reiter, A, Duncombe, A, Fanelli, T, Pietra, D, Rumi, E, Finke, C, Gangat, N, Ketterling, R P, Knudson, R A, Hanson, C A, Bosi, A, Pereira, A, Manfredini, R, Cervantes, F, Barosi, G, Cazzola, M, Cross, N C P, Vannucchi, A M, Tefferi, A

“…We recently defined a high-molecular risk category (HMR) in primary myelofibrosis (PMF), based on the presence of at least one of the five ‘prognostically…”
Get full text

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis by Tefferi, A, Pardanani, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Gangat, N, Finke, C M, Schwager, S, Mullally, A, Li, C-Y, Hanson, C A, Mesa, R, Bernard, O, Delhommeau, F, Vainchenker, W, Gilliland, D G, Levine, R L

“…High-throughput DNA sequence analysis was used to screen for TET2 mutations in bone marrow-derived DNA from 239 patients with BCR-ABL -negative…”
Get full text

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival by Tefferi, A, Lasho, T L, Huang, J, Finke, C, Mesa, R A, Li, C Y, Wu, W, Hanson, C A, Pardanani, A

“…The clinical relevance of JAK2 V617F allele burden in primary myelofibrosis (PMF) has not been previously studied. Bone marrow-derived DNA from 199 patients…”
Get full text

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients by Cerquozzi, S., Barraco, D., Lasho, T., Finke, C., Hanson, C. A., Ketterling, R. P., Pardanani, A., Gangat, N., Tefferi, A.

“…In a recent International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) study, prior arterial events and hypertension were…”
Get full text

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML by Tefferi, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Patnaik, M M, Hanson, C A, Pardanani, A, Gilliland, D G, Levine, R L

Get full text

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients by Lasho, T L, Finke, C M, Hanson, C A, Jimma, T, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Get full text

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis by Tefferi, A, Lasho, T L, Finke, C, Gangat, N, Hanson, C A, Ketterling, R P, Pardanani, A

Get full text

Calreticulin mutations and long-term survival in essential thrombocythemia by Tefferi, A, Wassie, E A, Lasho, T L, Finke, C, Belachew, A A, Ketterling, R P, Hanson, C A, Pardanani, A, Gangat, N, Wolanskyj, A P

“…The impact of calreticulin ( CALR ) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated…”
Get full text

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment by Barosi, G, Mesa, R A, Thiele, J, Cervantes, F, Campbell, P J, Verstovsek, S, Dupriez, B, Levine, R L, Passamonti, F, Gotlib, J, Reilly, J T, Vannucchi, A M, Hanson, C A, Solberg, L A, Orazi, A, Tefferi, A

Get full text

Mechanical and Microstructural Behavior of Tempered CPM® 3V High-Density Sintered Tool Steel by Hanson, Stephen A. C., Vadiraja, Sudhakar

“…The tempering response of CPM® 3V tool steel was investigated via a hardening and tempering heat treatment, tensile testing, fractography, and microstructural…”
Get full text

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients by Patnaik, M M, Hanson, C A, Hodnefield, J M, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

“…Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase ( IDH ) mutations in…”
Get full text

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia by Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A

“…Mutations involving epigenetic regulators ( TET2 ~60% and ASXL1 ~40%) and splicing components ( SRSF2 ~50%) are frequent in chronic myelomonocytic leukemia…”
Get full text

Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype by Patnaik, M M, Hanson, C A, Hodnefield, J M, Knudson, R, Van Dyke, D L, Tefferi, A

“…Monosomal karyotype (MK) refers to the presence of two or more distinct autosomal monosomies or a single monosomy associated with a structural abnormality. In…”
Get full text

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes by Pardanani, A, Finke, C, Lasho, T L, Al-Kali, A, Begna, K H, Hanson, C A, Tefferi, A

“…Recent studies suggest a powerful prognostic value for plasma cytokine levels in primary myelofibrosis (interleukin (IL)-2R, IL-8, IL-12, IL-15 and C–X–C motif…”
Get full text

Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome by Pardanani, A, D'Souza, A, Knudson, R A, Hanson, C A, Ketterling, R P, Tefferi, A

Get full text

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations by Patnaik, M M, Lasho, T L, Finke, C M, Gangat, N, Caramazza, D, Holtan, S G, Pardanani, A, Knudson, R A, Ketterling, R P, Chen, D, Hoyer, J D, Hanson, C A, Tefferi, A

“…The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with ‘myelodysplastic syndrome with isolated…”
Get full text